Literature DB >> 2419594

Stability and inactivation of HTLV-III/LAV under clinical and laboratory environments.

L Resnick, K Veren, S Z Salahuddin, S Tondreau, P D Markham.   

Abstract

The stability of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) under environmental conditions encountered in a clinical or laboratory setting and its inactivation by commonly used chemical disinfectants were investigated. Under our experimental conditions utilizing a highly concentrated viral preparation, virus with an initial infectious titer of approximately 7 log10 tissue culture infectious dose (TCID50) per milliliter can be recovered for more than a week from an aqueous environment held at room temperature (23 to 27 degrees C) or at 36 to 37 degrees C. Virus recovery is reduced at a rate of approximately 1 log10TCID50 per 20 minutes when held at 54 to 56 degrees C. Dried and held at room temperature, HTLV-III/LAV retains infectivity for more than three days with a reduction of approximately 1 log10TCID50 per nine hours. Viral infectivity is undetectable and reduced more than 7 log10TCID50 within one minute with 0.5% sodium hypochlorite, 70% alcohol, or 0.5% nonidet-P40, and within ten minutes with 0.08% quaternary ammonium chloride or with a 1:1 mixture of acetone-alcohol. These results help provide a rational basis to prevent the accidental spread of HTLV-III/LAV in the laboratory or clinical setting.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2419594

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  54 in total

Review 1.  The use of the dried blood spot sample in epidemiological studies.

Authors:  S P Parker; W D Cubitt
Journal:  J Clin Pathol       Date:  1999-09       Impact factor: 3.411

Review 2.  The sclera, the prion, and the ophthalmologist.

Authors:  J S Mehta; W A Franks
Journal:  Br J Ophthalmol       Date:  2002-05       Impact factor: 4.638

3.  Decontamination of an HIV-contaminated CPR manikin.

Authors:  I B Corless; A Lisker; R W Buckheit
Journal:  Am J Public Health       Date:  1992-11       Impact factor: 9.308

4.  Presence of human immunodeficiency virus nucleic acids in wastewater and their detection by polymerase chain reaction.

Authors:  S A Ansari; S R Farrah; G R Chaudhry
Journal:  Appl Environ Microbiol       Date:  1992-12       Impact factor: 4.792

Review 5.  Problems in pharmacokinetic investigations in patients with HIV infection.

Authors:  J D Unadkat; J M Agosti
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 6.  AIDS and the lung. 1--AIDS, aprons, and elbow grease: preventing the nosocomial spread of human immunodeficiency virus and associated organisms.

Authors:  P J Hanson; J V Collins
Journal:  Thorax       Date:  1989-10       Impact factor: 9.139

7.  Lipid composition and fluidity of the human immunodeficiency virus.

Authors:  R C Aloia; F C Jensen; C C Curtain; P W Mobley; L M Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

8.  Antimicrobial activity of UMFix tissue fixative.

Authors:  T J Cleary; A R Morales; M Nadji; M Nassiri; V Vincek
Journal:  J Clin Pathol       Date:  2005-01       Impact factor: 3.411

9.  Recovery of the human immunodeficiency virus from fibreoptic bronchoscopes.

Authors:  P J Hanson; D Gor; J R Clarke; M V Chadwick; B Gazzard; D J Jeffries; H Gaya; J V Collins
Journal:  Thorax       Date:  1991-06       Impact factor: 9.139

10.  Effects of supraphysiologic temperature and broth dilution on serum protein binding.

Authors:  R L White; M B Kays; T A Armstrong; L V Friedrich
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.